



Uloric[®] (febuxostat) – Safety update

- On November 15, 2017, the [FDA announced](#) that preliminary results from a post-marketing safety study showed an increased risk of heart-related death and death from all causes with [Uloric \(febuxostat\)](#) compared to [allopurinol](#).
- Uloric is indicated for the chronic management of hyperuricemia in patients with gout.
- Allopurinol is indicated for the following:
 - Management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
 - Management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.
 - Management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients.
- Healthcare providers should consider this safety information when deciding whether to prescribe or continue patients on Uloric.
- Patients should talk to their healthcare providers if they have any questions or concerns. Patients should not stop taking their medicine without first consulting with their healthcare provider.
- The Uloric drug label already carries a *Warning and Precaution* about cardiovascular events. Pre-approval studies showed a higher rate of heart attacks, strokes, and heart-related deaths with Uloric vs. allopurinol. As a result, the FDA required an additional post-marketing safety study to better understand these differences.
- The post-marketing safety study was conducted in over 6,000 patients with gout treated with Uloric or allopurinol. The primary outcome was a combination of heart-related death, non-fatal heart attack, non-fatal stroke, and a condition of inadequate blood supply to the heart requiring urgent surgery.
 - The preliminary results show that overall, Uloric did not increase the risk of these combined events compared to allopurinol.
 - However, when the outcomes were evaluated separately, Uloric showed an increased risk of heart-related deaths and death from all causes.
- The FDA is conducting a comprehensive review of this safety information and will update the public when more information is available.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.